Viatris Inc. (VTRS)
Manufactures and sells prescription drugs, generic medicines, and biosimilars worldwide.
$17.64+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+100.2%
The outlook
Viatris is trading near the top of its 52-week range, well above its major moving averages. Analyst consensus leans Buy, with an average price target sitting about 2% above the current price. The overall data picture appears constructive, though coverage is modest at eight analysts.
What’s behind the score
Analyst consensusBuy — 2.2 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range99% of the way from its 52-week low to high
Price targetAvg target +2% vs current price
Analyst price target
~12-month · 8 analysts$17.94average target+1.7% vs now
Now $17.64
Low $12.00High $23.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$20.54B
52-wk high
$17.75
52-wk low
$8.63
50-day avg
$16.39
200-day avg
$13.79
Trailing P/E
—